EP2666774A1 — Beta-lactamase Inhibitors
Assigned to Organon Pharma UK Ltd · Expires 2013-11-27 · 12y expired
What this patent protects
Substituted bicyclic beta-lactams of Formula I: are β-lactamase inhibitors, wherein a , X, R 1 and R 2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with β-lactam antibio…
USPTO Abstract
Substituted bicyclic beta-lactams of Formula I: are β-lactamase inhibitors, wherein a , X, R 1 and R 2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular, the compounds can be employed with a β-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to β-lactam antibiotics due to the presence of the β-lactamases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.